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Methods: Data from the US National Alzheimer’s Coordinating Center (n 5 3009) are used to
examine change in symptom status and to estimate transition probabilities between health states
described using cognitive function, functional ability, and behavior. A model is used to predict pro-
gression and to assess a hypothetical treatment scenario that slows mild to moderate AD progression.
Results: More than 70% of participants moved state over 12months. Themajority moved in domains
other than cognitive function. Over 5 years, of those alive more than half are in severe AD health
states. Assessing an intervention scenario, we see fewer years in more severe health states and a
potential impact (life years saved) due to mortality improvements.
Discussion: The model developed is exploratory and has limitations but illustrates the importance of
using a multidomain approach when assessing impacts of AD and interventions.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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The world-wide prevalence of Alzheimer’s disease and
other dementing disorders is predicted to increase from an
estimated 35.6 million in 2010 to 115.4 million in 2050
[1]. This is a clear marker for the growing importance and
the future challenges related to dementia. Alzheimer’s dis-
ease dementia (AD) represents an increasingly significant
health care burden on individuals, families, carers, and
health care systems [2,3]. The growing health care burden
of AD, aligned with competing demands on available
health care resources, presents health policy decision
makers with challenges, many of these linked to financial
and other resource use constraints associated with thethor. Tel.: 144 0 1392 722283; Fax:144 0 1392 42
green@exeter.ac.uk
16/j.jalz.2016.01.011
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).development and adoption of health and social care
services and also over the funding of future research. To
make the case for AD requires an increasing awareness
and understanding of the social and economic impact of
AD and intervention strategies to support those affected by
AD. In this context, decision analytic policy models are
commonly used, often with a public policy remit, to
investigate questions about the effectiveness and impact on
cost and health-related quality of life of a wide range of
health care interventions.
However, the development of methods to model the
impact of AD has been relatively slow. Advances in drug
therapies for AD over the 1990s led to improvements in
modeling methods to support claims for the adoption of
these new treatments. Earlier reviews [4,5] report that
modeling methods in AD have often used a simplified
representation of the underlying disease and symptom
structure for AD, commonly considering only cognitive
function, and that these models may have limitations inimer’s Association. This is an open access article under the CC BY-NC-ND
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recent years, we have seen a continued growth in the
evidence base on the methods available to model the
progression of AD; yet, there remains a reliance on the use
of cognitive function in the assessment of the impacts of
AD and the likely effectiveness of intervention strategies
(see Supplementary Table A).
Although cognitive function is a defining and central fac-
tor in AD, the original description of AD included behav-
ioral and psychotic symptoms along with memory loss [6].
The diagnosis of AD includes requirements for both cogni-
tive impairment and substantial impairment in daily func-
tioning or behavioral symptoms (NINCDS-ADRA) [7].
Changes in one or more of these domains provide the basis
for assessing severity and progression of AD [8]. However,
research on the modeling of AD has emphasized cognitive
decline over loss of functional ability and behavioral symp-
toms, such as psychosis, agitation and depression. This com-
mon conceptualization, with cognition often as the only
predictive variable, may limit our ability to estimate the
impact of AD and the potential benefits of intervention stra-
tegies.
Results from recent multivariate research in AD [9]
recommend that the most appropriate approach to model
AD and its progression involves incorporating the symptom
domains of cognition, behavior, and function. Responding to
such recommendations, we take a simple conceptual multi-
domain model of AD progression (See Fig. 1 [4]), using
these three symptom domains, and operationalize this model
using available data. The aim was to demonstrate the utility
of a multidomain approach to modeling progression of ADHealth state j
CogniƟon [1, 2, or 3]
Behavior [1, 2, or 3]
FuncƟon [1, 2, or 3]
Health state n
CogniƟon [1, 2, or 3]
Behavior [1, 2, or 3]
FuncƟon [1, 2, or 3]
Health state i
CogniƟon [1, 2, or 3]
Behavior [1, 2, or 3]
FuncƟon [1, 2, or 3]
Fig. 1. Schematic for Multi Domain AD Progression Model. The figure presents
model, showing AD health sates (states i, j,.n) described using cognitive functio
levels (categories of severity). Death is a health state (absorbing state) in the modand to provide a foundation from which to develop a model
to support the health policy context.
2. Methods
2.1. Participants
We use the Uniform Data Set (UDS) from the US Na-
tional Alzheimer’s Coordinating Center (NACC) [10,11].
The UDS contains data from the Alzheimer disease
centers (ADCs) across the United States. All ADCs enroll
and follow participants annually and provide pooled data
for research through the NACC. Diagnoses are assigned
using clinical criteria. The NACC UDS includes data on
cognitive function, functional impairment, and behavior;
using the Mini-Mental State Examination (MMSE) [12],
Functional Assessment Questionnaire (FAQ) [13], and the
Neuropsychiatric Inventory (NPI) [14]. We limited data an-
alyses to those participants who were aged 50 years, have
an MMSE score of 26, and have continuous data collected
over time on at least two consecutive assessments, including
a diagnosis of probable AD and MMSE data. We included
participants with a diagnosis of probable AD on entry to
the data set, and also those that were known to ADCs before
having a diagnosis of probable AD. We extracted data from
eligible participants with complete data on MMSE, FAQ,
and NPI-Q in March 2014.
2.2. Descriptive system for Alzheimer’s dementia
A multidomain descriptive system is used, capturing the
three primary symptom domains of AD; cognitive function,Death
the conceptual model and schematic for the multi domain AD progression
n, behavior, and functional ability, with each domain described using three
el.
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categorical approach is used to place impairments on each
of the domains into one of three severity levels, covering
no or mild problems, moderate problems, or severe problems
(see Table 1). This approach is consistent with the typical
interpretation of the rating scales used to assess symptomatic
problems in AD, see below. There is a broad range of rating
scales, and clinical measures available to assess health status
and impairment, and here, we use the MMSE, NPI-Q, and
the FAQ, as proxy measures for cognitive function, behavior
and mood, and functional impairment.
2.2.1. MMSE
The MMSE [12] is a clinician administered measure to
assess global cognitive functioning. Although there is no
range of scores that can be rigidly and universally applied
to indicate dementia severity, mild AD is often associated
with an MMSE of 21 to 26, moderate AD with an MMSE
of 10 to 20 and severe AD with an MMSE of,10. This sim-
ple categorization of AD cognitive function, as commonly
used in a policy setting (e.g., UK NICE [15]) is applied here.
2.2.2. NPI-Q
The NPI-Q [14] is a brief 10-item questionnaire derived
from the Neuropsychiatric Inventory (NPI) [16], a validated
clinical instrument for evaluating psychopathology in de-
mentia. It assesses 10 behavioral domains common in de-
mentia, and each of these domains where present are
scored 1–3 for severity: 1 as mild (e.g. present but not dis-
tressing/disruptive to the person with dementia), 2 moderate,
and 3 as severe. Here, consistent with the approach used by
Spalleta et al. [17], we categorize behavior and mood into
three severity levels, with no or mild problems where all
items are scored at 1 or 0, severe problems when at least
one of the items is scored at 3, and moderate problems
when at least one item is scored at 2, with all others at 2.
2.2.3. FAQ
The Functional Activities Questionnaire (FAQ) [13] is
an informant-based assessment on 10 activity items for the
person with dementia, with each scored on four levels
(from 0–3) ranging from dependence to independence
(3 5 dependent, 2 5 requires assistance, 1 5 has difficulty
but does by self, 0 5 normal). The items also have a “notTable 1
Descriptive system for AD: Definition by level of severity for each symptom dom
Domain Severity level Label
Cognitive function Mild [1]
Moderate [2]
Severe [3]
Behavior & Mood No problem/mild [1]
Moderate [2]
Severe [3]
Functional Ability No problem [1]
Moderate [2]
Severe [3]applicable” response category. The FAQ is scored at 0–30,
derived using the mean scores for the applicable items multi-
plied by 10, where higher scores indicate greater functional
impairment and dependence. A score of eight or below is
regarded as no problems, and a score of 24 or above is
indicated as being more severely affected and highly
dependent [13].2.3. Statistical analyses
Participants included in the analyses are allocated into
the descriptive system defined here (Table 1), at each time
point, using participant level data on each symptom
domain. The mean change in domain specific score is
described, and the proportion of people moving between
domain specific categories is described. The frequency
of moves between health states is described, and the tran-
sitions between states are calculated to derive transition
probabilities between states. Transition probabilities are
estimated using a fixed cohort approach, defined as
ðN02NtÞ=N0, where N0 represents the size of the popula-
tion eligible to transit to a state at the beginning of the
time interval, and Nt represents the number remaining
eligible to transit at time t [18]. The size of the transition
matrix precludes use of a dynamic cohort approach
(where probabilities are derived from estimated rates),
within the constraints of the current research.2.4. Modeling framework
Using the transition probabilities derived here, we predict
the progression of AD, applying a 1-year cycle length over a
5-year time horizon, for a hypothetical cohort with mild to
moderate AD. We use a mild to moderate AD cohort as
an example here as this is currently the treatment eligible
population for cholinesterase inhibitors, although the
modeling framework predicts separately by health state
and allows prediction by specific severity categories (e.g.,
for mild and/or moderate AD). The starting distribution of
the cohort, over eight health states, is based on observed
proportions in mild to moderate AD states in the NACC
data used, using mild and moderate states where no severe
symptoms are present, comprising 69.5% mild and 30.5%
moderate AD (see Table 2). Using estimated annualain
Definition
21  MMSE  26
10  MMSE 20
0  MMSE  9
NPI-Q: each item  1
NPI-Q: each item  2; with at least one item equal to 2
NPI-Q: at least one item equal to 3
0  FAQ total  8
9  FAQ total  23
24  FAQ total  30
Table 2
Multi domain descriptive system for AD, and participants (NACC-UDS,
n 5 3009) by location
Domain severity level
State
name
State
severity
label
Number
at
baseline
Number at
12-month
follow-upCognition Behavior Function
1 1 1 111 Mild* 455 226
1 1 2 112 Mild* 581 444
1 1 3 113 Moderate 63 79
1 2 1 121 Mild* 101 44
1 2 2 122 Mild* 354 249
1 2 3 123 Moderate 56 82
1 3 1 131 Moderate 29 12
1 3 2 132 Moderate 97 84
1 3 3 133 Moderate 33 46
2 1 1 211 Moderate* 77 54
2 1 2 212 Moderate* 361 386
2 1 3 213 Moderate 159 245
2 2 1 221 Moderate* 20 14
2 2 2 222 Moderate* 191 207
2 2 3 223 Moderate 158 253
2 3 1 231 Moderate 5 5
2 3 2 232 Moderate 59 73
2 3 3 233 Severe 76 161
3 1 2 312 Severe 9 28
3 1 3 313 Severe 34 100
3 2 2 322 Severe 6 10
3 2 3 323 Severe 57 106
3 3 2 332 Severe 2 4
3 3 3 333 Severe 26 96
3 1 1 311 Severe 0 1
3 2 1 321 Severe 0 0
3 3 1 331 Severe 0 0
Columns 1–3: 1 refers to mild in cognition, no problem/mild in behavior,
no problem in function; 2 refers to moderate in cognition, behavior and
function; 3 refers to severe in cognition, behavior and function.
*These eight health states are used to define a cohort of people with mild
to moderate AD, i.e., 21% in state 111, 27% in state 112, and so on (see
Table 5; showing 69.5% mild, 30.5% moderate AD). The defined cohort
is used to demonstrate the application of the modeling framework in a health
policy context.
Table 3
Participant baseline demographic and clinical characteristics (N 5 3009)*
Age (mean, SD, range) 75.59, 9.19, (50–104)
Male 44.10%
Years of education (mean, SD, range) 14.60, 6.64, (0–25)
Race (%)
White 82.98
Black or African American 11.67
Other 5.35
Language (%)
English 92.66
Spanish 5.72
Other 1.62
Living situation (%)
Alone 15.82
Spouse/Partner 66.4
Relative or Friend 12.89
Other 4.89
Independence (%)
Able to live independently 21.77
Requires some assistance with
complex activities
52.87
Requires some assistance with
basic activities
20.31
Complete dependent 4.75
Unknown 0.3
Residence (%)
Single family 87.67
Retirement community 5.52
Assisted living/boarding/adult family home 3.86
Skilled nursing home 1.13
Other 1.82
Informant (%)
Spouse/partner 61.28
Child 29.43
Other 9.29
MMSE (mean, SD, range) 20.24, 5.08, (0–26)
NPI-Q-10 (mean, SD, range) 3.55, 3.76, (0–26)
FAQ (mean, SD, range) 15.82, 8.50, (0–30)
*We have not assessed data on AD medication use, but Spackman et al
[27] report data from the NACC-UDS in a similarly defined cohort
(n 5 3852) where 70% of participants report taking an AD drug (cholines-
terase inhibitors or memantine).
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of each cycle and assess two scenarios for mortality, using
(1) a simplifying assumption of a standard annual mortality
rate (10% pa [19–22]) across all people with AD, and (2)
differential annual mortality risks by mild, moderate, and
severe AD (see Table 5). This simple modeling framework
is used to assess the value of the multidomain approach in
a health policy context.
We predict the expected progression for a cohort of peo-
ple with mild to moderate AD (controls) and compare this
with the predicted progression of AD where that same
cohort, starting in the same states, are subject to a hypothet-
ical treatment scenario in year one, with a simulated treat-
ment effect reflected through a delay in the expected
disease progression. This treatment scenario is used to simu-
late the potential effect of a future health intervention,
providing an improvement in health status (health state loca-
tion) during year one. We make a conservative assumption
that 20% of the treated cohort receives a treatment effectthat delays the expected (control cohort) progression of
AD (i.e., people remain in the same state at year 1 to year
2, when they would otherwise be expected to move to a state
with greater impairment in year 2). We compare the differ-
ence in progression of AD, controls versus the treatment
scenario, in a cohort with mild to moderate AD, describing
the proportion of the starting cohort in mild, moderate, and
severe health states over time, and by comparing the
number of years in each of these different severity states
over a 5-year time horizon.3. Results
At the time of data collection, we extracted data from the
NACC UDS on 3009 participants with complete data and
meeting the inclusion criteria. Most of the participants ex-
tracted had a diagnosis of probable AD on entry to the
NACC data set (n 5 2448, 81%). Table 3 presents the
Table 4
Transition matrix for the 20 state AD progression model (transition probabilities between health states)
From state
To state
111 112 113 121 122 123 131 132 133 211 212 213 221 222 223 232 233 313 323 333
111 0.38 0.23 0.02 0.05 0.07 0.01 0.01 0.01 — 0.07 0.09 0.01 0.01 0.02 0.00 0.01 0.00 0.00 — —
112 0.03 0.34 0.04 0.01 0.14 0.03 — 0.02 0.01 0.01 0.18 0.07 0.00 0.05 0.04 0.02 0.02 0.01 0.01 0.00
113 — 0.05 0.14 — 0.02 0.06 — 0.02 0.08 — 0.03 0.25 — — 0.19 0.02 0.13 — — 0.02
121 0.16 0.26 0.01 0.11 0.15 — 0.01 0.07 — 0.02 0.07 — 0.02 0.10 — 0.03 — — — —
122 0.02 0.18 0.04 0.01 0.21 0.06 0.01 0.07 0.03 — 0.12 0.03 0.01 0.09 0.05 0.03 0.04 0.00 0.01 0.01
123 — 0.02 0.05 — 0.04 0.20 — — 0.07 — 0.05 0.18 — 0.05 0.18 — 0.13 — 0.04 —
131 0.10 0.10 0.03 0.10 0.17 — 0.07 0.14 0.03 0.07 — — — 0.07 — 0.10 — — — —
132 — — 0.04 0.03 0.15 0.05 0.01 0.18 0.08 — 0.03 0.07 — 0.09 0.07 0.10 0.07 0.01 — —
133 — — 0.06 — 0.03 0.21 — 0.03 0.15 — — — — — 0.21 0.03 0.27 — — —
211 0.08 0.12 0.03 — 0.06 — — — — 0.10 0.36 0.05 0.01 0.08 0.01 0.03 0.01 0.05 — —
212 0.01 0.07 0.01 — 0.02 0.01 0.00 0.01 — 0.01 0.32 0.14 0.00 0.12 0.09 0.03 0.04 0.07 0.03 0.02
213 — 0.01 0.04 — — 0.01 — — 0.01 — 0.06 0.33 — 0.03 0.17 — 0.07 0.12 0.11 0.05
221 0.05 0.15 — — 0.05 — — — — 0.10 0.20 — — 0.20 0.05 0.15 0.05 — — —
222 0.01 0.04 0.01 — 0.04 0.02 — 0.01 0.02 0.01 0.14 0.10 — 0.15 0.17 0.06 0.10 0.05 0.03 0.06
223 — — — — — 0.03 — — — — 0.03 0.14 — 0.03 0.30 0.02 0.16 0.10 0.11 0.08
232 — 0.02 0.05 — 0.03 0.02 — 0.10 0.02 — — 0.11 0.02 0.24 0.06 0.10 0.11 0.08 0.03 0.03
233 — — — — — 0.01 — — 0.04 — 0.01 — — 0.03 0.30 0.01 0.26 0.04 0.08 0.22
313 — — — — — — — — — — 0.02 — — — 0.02 — 0.02 0.42 0.37 0.14
323 — — — — — — — — — — — 0.02 — — 0.03 — 0.02 0.29 0.43 0.22
333 — — — — — — — — — — — — — 0.04 0.04 — 0.04 0.04 0.25 0.61
NOTE. See Table 1 for descriptive system.
NOTE. State 231 is merged with 232, 312 with 313, 322 with 323, and 332 with 333.
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symptom domains reflected a worsening of health status
over time, with a mean (SD) decline on each domain over
the initial 12-month follow-up of 2.28 (0.15) points on
MMSE, 0.6 (0.10) points on the NPI-Q, and 3.8 (0.21) points
on the FAQ. Most people experienced deterioration in symp-
tom scores over months 0–12, but an improvement is re-
ported for a significant proportion of participants, most
notably for behavior and mood (NPI-Q). A worsening of
scores on cognitive function, behavior and mood, and func-
tion was reported for 2043 (68%), 1378 (46%), and 2180
(72%) participants respectively; with improvements
reported by 600 (20%), 1021 (34%), and 496 (16%) partic-
ipants respectively. Table 2 presents the location of partici-
pants at baseline (n 5 3009) across the health state
descriptive system. Three health states were not populated
(321, 331, and 311) and four states (231, 312, 322, 332)
were unlikely to be populated (i.e., ,10 participants) and
were merged with adjacent (next highest) states, resulting
in a set of 20 states for the model presented here. Over the
0–12 month follow-up, 2174 people (.72%) moved health
state, with 835 remaining in their starting state. In those
moving state, the majority (n 5 1,247, 57%) moved due to
a change in only one symptom domain, with 897 of these
(.70%) being unrelated to the cognitive score. In addition,
one third of those moving states due to multiple symptom
changes were unrelated to cognitive function. Although
the majority worsened on health status, a large number
(n5 352, 16%) moved state due to an improvement in their
health status, most commonly (220 of 352) due to reported
symptoms on behavior and mood (NPI-Q).In participant data identified here, 50% (n 5 1491) of
participants provided data with 24-month follow-up, and
25% (n 5 734) provided data with 36-month follow-
up. We estimate transition probabilities using a fixed
cohort approach using data over a 0–12-month follow-
up from 3009 participants and do not combine data
from the three groups of participants with differential
follow-up (1, 2, and 3 year follow-up). Table 4 presents
the transition probabilities estimated. In this table, we
see that for many of the health states there is a high
probability of moving to a different state over a 12-
month period, some of these transitions can be to states
that may be similar in terms of severity or may reflect
an improvement in health status, but in many instances
and especially for mild and moderate AD, the
transitions are to states that reflect a worsening of health
status. For example, for states 112, 121, 122, 211, and
212, between 46% and 63% of people are predicted to
move to a health state the represents a clear worsening
of AD severity.
Table 5 presents the predicted progression of AD over
5 years for a cohort with mild to moderate AD. When us-
ing a standardized mortality rate for AD (C1), we see that
of those alive after 5 years over half are in severe AD
health states. Only 5.3% of the starting cohort (69.5%
start in mild states) are alive in mild AD states after
5 years, with 41% of the total cohort having died over
this time. In this scenario, the cohort (controls, C1) spends
120, 179, and 90 years in mild, moderate and severe AD
states, respectively, over 5 years, with mortality account-
ing for 111 years over that period. When predicting
Table 5
Predicted AD progression over time (month 0–60) by group (control and hypothetical treatment cohorts) and by mortality scenario
Time point
Proportion participants, at the end of month Life years (in state)
Group Mild Moderate Severe Death Group Mild Moderate Severe Death
Start Distribution 69.50 30.50 0.00 0.00
Month 12 C1 38.57 44.13 7.30 10.00 C1 54.04 37.31 3.65 5.00
T1 48.49 37.08 4.43 10.00 T1 58.99 33.79 2.21 5.00
C2 40.50 37.83 4.22 17.45 C2 55.00 34.16 2.11 8.73
T2 50.91 31.95 2.56 14.58 T2 60.21 31.22 1.28 7.29
Month 24 C1 22.46 42.56 15.98 19.00 C1 30.52 43.35 11.64 14.50
T1 27.64 41.24 12.12 19.00 T1 38.06 39.16 8.28 14.50
C2 24.06 33.31 7.25 35.38 C2 32.28 35.57 5.73 26.41
T2 29.85 33.10 5.71 31.34 T2 40.38 32.52 4.14 22.96
Month 36 C1 13.48 36.49 22.94 27.10 C1 17.97 39.52 19.46 23.05
T1 16.3 37.16 19.43 27.10 T1 21.97 39.20 15.78 23.05
C2 14.42 25.98 8.19 51.41 C2 19.24 29.65 7.72 43.39
T2 17.7 27.54 7.40 47.31 T2 23.80 30.32 6.56 39.32
Month 48 C1 8.33 29.75 27.53 34.39 C1 10.90 33.12 25.24 30.75
T1 9.9 30.98 24.71 34.39 T1 13.12 34.07 22.07 30.75
C2 8.74 19.00 7.69 64.58 C2 11.58 22.49 7.94 57.99
T2 10.7 20.86 7.50 60.97 T2 14.21 24.20 7.45 54.14
Month 60 C1 5.26 21.98 31.81 40.95 C1 6.80 25.86 29.67 37.67
T1 6.17 23.16 29.72 40.95 T1 8.05 27.07 27.21 37.67
C2 5.33 12.79 6.90 74.98 C2 7.03 15.90 7.29 69.78
T2 6.47 14.36 7.10 72.08 T2 8.57 17.61 7.30 66.52
Total life years
C1 120.22 179.16 89.65 110.97
T1 140.19 173.29 75.55 110.97
C2 125.14 137.77 30.79 206.30
T2 147.16 135.88 26.72 190.23
NOTE. Group specifications are as follows: C1 5 Control group 1, no treatment effect, 10% constant mortality rate; T15 Treatment group 1, 20% (20 per
100) receiving treatment effect, 10% constant mortality rate; C2 5 Control group 2, no treatment effect and variable mortality by severity of AD;
T2 5 Treatment group 2, 20% (20 per 100) receiving treatment effect, and variable mortality by severity of AD.
The variable annual mortality rates by AD severity at 5.5% Mild, 21.5% Moderate and 48% Severe (Spackman et al [27]).
The simulated treatment effect adjusts progression in year 1 to reflect 20 persons expected to move to a worse health state remain in their starting state (i.e.
20% of participants receive a treatment effect).
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treatment effect is applied, retaining the assumption of a
standardized mortality rate (T1), we see fewer years in
the more severe states, with 140, 173, and 76 years in
mild, moderate, and severe states, respectively, with
mortality held constant compared to the control cohort.
Assessing a scenario with mortality rates applied by
AD severity, with a much increased risk of death per
year in moderate and severe states, applied to the same
starting cohort (C2 and T2), we see marked differences
in the comparison between controls (C2) and the hypo-
thetical treatment cohort (T2). In this scenario, controls
spend 125, 138, and 31 years in mild, moderate, and se-
vere AD states, respectively, over 5 years, with mortality
accounting for 206 years over that period. When predict-
ing progression for the same cohort scenario, applying
mortality rates by AD severity, but additionally with a
hypothetical treatment effect applied, we see a marked
mortality impact with the treatment effect resulting in
an increase in life years lived. In this treatment scenario
(T2), the cohort spend 147, 136, and 27 years in mild,
moderate, and severe AD states, respectively, over5 years, with mortality accounting for 190 years over
that period, a reduction of 16 years in the impact of mor-
tality on this cohort of 100 people over 5 years.4. Discussion
Here, we report that many people with AD change
health status, in a potentially important way, through
changes in either behavior or in functional impairment,
either with or without a decline in cognitive function.
Prior reports of the annual rate of change on MMSE
[23] and the magnitude of the annual rates of change in
behavior and function [24] are consistent with those re-
ported here. To date, the assessment of interventions, in
many instances, has focused on the impacts of AD in
relation to cognitive function. Results here indicate that
this may be an overly narrow focus on the impacts of
AD. We highlight the multidomain nature of AD and
the importance of looking beyond cognitive function.
Prior studies [9,23–25] have reported the fluctuating
nature of symptom scores, particularly the episodic
nature of behavioral symptoms, and longitudinal
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scores for cognition, function, and behavior in people
with AD can improve as well as decline, as reported in
the data here.
In a health policy context, the challenge is often to
compare alternative intervention strategies to estimate dif-
ferences in health outcomes and costs. For AD, this requires
assessment of the progression of dementia, and here, we
explore how this can be done using the model presented,
applying an adjustment to the transition probabilities for a
“treated” cohort to impact on the predicted progression
profile in that cohort, for comparison with the control cohort
of people with mild to moderate AD. Similarly, a difference
could be estimated based on different starting distributions
across health states for a comparison of cohorts with
AD. For example, using individual participant level data
available at the end of a clinical trial, where a treatment
has been able to alter the symptom domain scores across
one or all the three symptom domains used here.
In the comparative scenario presented here, using a rela-
tively modest although hypothetical expected intervention
effect, with 20% of participants in a treatment scenario
experiencing a meaningful positive effect from treatment,
we report data to suggest an improvement in health status
where annual mortality impact (rate) is held constant be-
tween groups. Where a potentially more realistic scenario
is explored on mortality data, with increasing rates of mor-
tality as AD progresses to more severe stages, we see an
improved health status profile in the scenario with a simu-
lated treatment effect, and we see a positive impact on the
expected mortality compared to the control cohort. To put
such differences into context, prior cost effectiveness ana-
lyses have reported relatively small differences in out-
comes over time. For example, Bond et al. report an
evaluation comparing cholinesterase inhibitors with best
supportive care in mild to moderate AD, using a 20-year
time horizon, finding differences of 0.03 to 0.04 quality-
adjusted life years (QALYs) and a difference of 1.5 months
in time to institutionalization [26].
We are aware of other promising approaches tomodel AD
in a multidomain framework. For example, Spackman et al.
[27] have reported transition probabilities for AD, by disease
severity (mild, moderate, and severe) and care setting (com-
munity and institutional), using NACC-UDS data linked to
the Clinical Dementia Rating (CDR) scale. The CDR is
used to assess cognitive and functional performance in six
areas; however, memory (cognitive function) is the primary
area, and the CDR reflects the memory score unless three or
more of the secondary categories score above or below the
memory score [28]. In the transition probabilities presented
by Spackman et al., the progression from mild to moderate
AD over time is relatively slow. For example, where people
are in mild AD, they have a 0.77 probability or remaining in
a mild AD state over 12 months (if moderate AD, a 0.58
probability of remaining in moderate or moving to mild
AD). See Supplementary Table B for a comparison of thetransitions reported by Spackman et al. with those
presented here. Stallard et al. [29] have presented a multidi-
mensional model of the course of AD, using Grade of
Membership (GoM) statistical techniques to consider large
amounts of data on individuals with AD. The GoM model
can represent multiple attributes including measures of
cognitive functioning, function and behavior and mood,
alongside other participant characteristics and is a promising
approach. However, it appears technically challenging for
analysts who require a methodology to apply based on sec-
ondary data and evidence synthesis methodology. Other
than the initial application from Stallard et al. [29], to assess
the impact of AD progression on costs, the GoM model has
not been applied in a health policy context. Other studies
have presented multidomain modeling (see Supplementary
Table A), but none to date to our knowledge afford each of
the symptom domains equal standing, as is the case in the
model presented here.4.1. Limitations
We develop a simple descriptive system covering the de-
mentia stage of Alzheimer’s disease. The descriptive system
is based on the three main symptom domains with three
levels of severity for each of the symptoms. Although the
descriptive system is simple and seeks to be practical, and
it still provides a set of up to 27 health states (27! 27 tran-
sitions, in theory), it may not capture the impacts of AD
in some areas. For example, where there are changes in
symptom domain scores these may not lead to a change in
health state, albeit evidence suggests that there are cost im-
pacts associated with incremental changes on domains such
as cognition [30] and behavior [31]. However, a more com-
plex descriptive system is considered impractical for the
currently available data.
We acknowledge that the data used are from
commonly applied measurement instruments, and that
there are practical and methodological concerns with
many of the instrument used in AD [32] including those
used here. However, we would contend that the descrip-
tive system here may be generalizable to other judgments
on severity categories when other measurement instru-
ments are used (available) given the broad approach
taken to categorizing no or mild, moderate (some), and
severe problems. However, empirical investigation is
required to support this assertion.
The descriptive system covers a wider range of health
states (20 states) than typically seen in other models for
AD; however, in the current analyses, we have reduced the
descriptive system to three categories of AD severity
(mild, moderate, and severe) for purposes of presentation.
In the next stage of model development, we expect to esti-
mate resource use (costs) and a summary measure of
health-related quality of life (i.e., health state values,
QALY weights) for each of the states. This will allow the
model to be demonstrated more fully and to be tested in a
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basis for comparison of interventions.
In the current presentation of the model, using simplified
AD severity categories of mild, moderate, and severe,
applying data estimated in Table 5, we estimate here UK
costs and QALY outcomes over time (5 years), for illustra-
tive purposes only. We have used annual cost estimates of
£6300, £7704, and £11,640 for health and social care service
costs for mild, moderate, and severe AD health states [3].We
have used health state values (QALY weights) of 0.71 and
0.64 for mild and moderate AD health states [3], and 0.38
for the severe AD health state [33]. We discount future costs
and benefits at a rate of 3.5% per year [34,35]. In a
comparison of the control and hypothetical treatment
cohorts (C1 and T1, Table 5), we estimate a mean QALY
gain of 0.05 over 5 years, and a saving in care costs of
approximately £800 (excluding any additional treatment
costs). In a comparison of cohorts where mortality rates
are based on AD severity (C2 and T2, Table 5), we estimate
a mean QALY gain of 0.12 and an additional care cost of
£670 (excluding any additional treatment costs). This latter
scenario demonstrates the perverse finding in decision ana-
lytic models of AD whereby improving mortality increases
costs of care (due to the longer period lived and requiring
care costs) and acts as a penalty on an effective intervention.
These crude decision-analytic data are based on what may be
regarded as a modest hypothetical effect, and on cost data
which may not fully reflect the true costs of patients in severe
states, and it is only presented here for illustrative purposes.
We suggest that the illustration here does not capture the
potential of the modeling framework presented here. We
expect that in a future full application of the model, in a
decision-analytic context, where health state costs and
health state values are estimated based on the descriptive
system used, analyses will be more detailed and potentially
more useful in a policy context.
The NACC UDS is a large database of standardized clin-
ical data but we acknowledge that there may be limitations
linked to the generalizability of the sample used here. Sample
characteristics indicate a broadly representative sample of
people with a diagnosis of probable AD, but readers are
advised to consider generalizability in specific applications
of the model. Although we do not report specific data on
the number of participants taking an AD drug (cholinesterase
inhibitors or memantine), prior reports of this sample [27]
indicate that most of the participants will be onAD drug treat-
ment when data are collected. Applying core inclusion
criteria here, including the availability of data on cognitive
function (MMSE) over two consecutive time points resulted
in a potential participant sample of n 5 3316. However, the
absence of data on function (FAQ) or behavior (NPI-Q) re-
sulted in the exclusion of 307 participants, and this may
have led to some bias in the data used. Although it is not
possible to suggest the likely direction of that bias (i.e., a
less severe or more severe participant sample), the relatively
small number of exclusions may limit the impact of such bias.We present results from the use of the transition probabil-
ities and modeling framework over a 5-year time horizon,
to demonstrate the approach, and are aware this may be a
limitation in some settings given expected survival rates
may be longer in some people with AD. We have therefore
provided results from modeling the same mild to moderate
cohort of people with AD, using different mortality assump-
tions (cohorts C1 and C2), over a 10 year time period, see
Supplementary Table C.
The transition probabilities estimated are based on
follow-up over a 0–12 month duration, and this is a potential
limitation in the approach. Ideally, we would like to have a
longer follow-up period, over subsequent years, but the na-
ture of AD leads to a loss to follow-up in observational
studies and to a challenge created by truncated data. We
have chosen to present transit probabilities based on the
observed data, across a generalized participant cohort with
AD, rather than to apply statistical methods to adjust for
censored data (e.g., survival analysis methods) or to stratify
analyses or data by participant characteristics. Across the
matrix of transit probabilities, a large data set is preferable
to capture the evaluative space, and stratifying by character-
istics would introduce limitations with the data (i.e. lack of
coverage across the transition matrix). However, in
Supplementary Table D, we present the transition probabil-
ities estimated over an alternative scenario, using participant
data “pooled” over all time periods, regardless of whether
participants contribute 1, 2, or 3-year of follow-up data.
Assuming time independence for transitions over a 12-
month time period, this provides 5234 data points on transi-
tions between states over a 12-month period. In this scenario,
applying transit probabilities estimated from “pooled” data,
which we consider the most appropriate comparison (from
available data) to our primary results, we present
Supplementary Table E on predicted progression of AD
for comparison with data in Table 5, with results broadly
similar.
A further limitation is the absence of a clear evidence
base on the mortality rates for AD by disease severity.
Although evidence suggests an increasing mortality risk
where AD severity worsens, there is a sparsity of data to
inform on mortality rates by severity. Here, we use data
from a prior study reporting on the participants in the
NACC UDS, which presents a steep gradient on annual mor-
tality risk (from 5% to 48%) by AD severity [27]. There is
evidence to support the high mortality rate reported here,
and applied in the current analyses, from studies reporting
relative risks across AD severity [36,37].
We have been unable to compare the predicted progres-
sion of AD with observed data, as a means of validating
the model, and we therefore acknowledge this as a limitation
with the approach presented.We have provided a simple pre-
sentation on the comparison of transition probabilities re-
ported here, and those reported by Spackman et al [27] in
Supplementary Table B, using a cohort of people with
mild to moderate AD. Validation of modeling methods is a
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from this limitation, given limited opportunities to access
publicly available data. We hope to be able to further
develop this aspect of the current research, to offer greater
confidence that the modeling methods may provide a poten-
tial improvement in modeling methods for AD. At the pre-
sent time, we have only been able to obtain data from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
[http://www.adni-info.org/], and the data available from
ADNI are for a relatively small number of participants,
with participants in ADNI not commonly regarded as typical
of the current clinical population of people with AD [38].
5. Conclusion
Although exploratory, the analyses presented here are
able to demonstrate how a simple multidomain approach
to the description of AD and the use of a simple and practical
descriptive system to model the reported change in health
status over time, using measures for cognitive function,
behavior and mood, and functional ability, may enhance
the evaluative framework for the assessment of interventions
for AD. Evidence to further support the modeling framework
needs to be accumulated over time.
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1. Systematic review: Health policymodels used to pre-
dict the progression of Alzheimer’s disease dementia
have been reviewed by Green et al [3], with literature
updated to 2013 here. The literature reports that
cognitive function is used in most instances to predict
progression of AD, and that this approach may not
capture the impact of AD and/or interventions for
AD.
2. Interpretation: The findings from our research pro-
vide empirical evidence to reinforce the importance
of modeling AD over time in a multidomain manner.
We report that many people with AD change health
status in a meaningful way in domains other than
cognition. We develop and present a multidomain
health policy approach to demonstrate the value of
predicting the progression of AD in this way.
3. Future directions: The model developed is illustra-
tive, and further research is required to validate the
approach and to test out the model in a decision an-
alytic context.
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